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Abstract 
Systemic sclerosis (SSc) is an often fatal disease characterized by autoimmunity and inflam-
mation, leading to widespread vasculopathy and fibrosis. Lysophosphatidic acid (LPA), a 
bioactive phospholipid in serum, is generated from lysophospholipids secreted from acti-
vated platelets in part by the action of lysophospholipase D (lysoPLD). Sphingosine 
1-phosphate (S1P), a member of the bioactive lysophospholipid family, is also released from 
activated platelets. Because activated platelets are a hallmark of SSc, we wanted to deter-
mine whether subjects with SSc have altered serum lysophospholipid levels or lysoPLD ac-
tivity. Lysophospholipid levels were measured using mass spectrometric analysis. LysoPLD 
activity was determined by quantifying choline released from exogenous lysophosphatidyl-
choline (LPC). The major results were that serum levels of arachidonoyl (20:4)-LPA and S1P 
were significantly higher in SSc subjects versus controls. Furthermore, serum LPA:LPC ratios 
of two different polyunsaturated phospholipid molecular species, and also the ratio of all 
species combined, were significantly higher in SSc subjects versus controls. No significant 
differences were found between other lysophospholipid levels or lysoPLD activities. Elevated 
20:4 LPA, S1P levels and polyunsaturated LPA:LPC ratios may be markers for and/or play a 
significant role in the etiology of SSc and may be future pharmacological targets for SSc 
treatment. 
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Introduction 
Systemic sclerosis (SSc) is an often fatal disease 
characterized by autoimmunity and inflammation, 
leading to widespread vasculopathy and fibrosis of 
multiple organs (1). There are two distinct subsets of 
the disease, limited and diffuse, which are based on 
the extent of skin involvement. These subsets may 
have different clinical and laboratory findings (2). 
However, one of the hallmarks of the vasculopathy 
associated with both subsets of SSc is platelet activa-
tion, which has been implicated as a key mediator of 
the fibrosis that underlies SSc (3). 
Phospholipid growth factors (PLGFs) are a fam-Int. J. Med. Sci. 2009, 6 
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ily of lipids with growth factor-like properties. Lyso-
phosphatidic acid (LPA) is a member of the PLGF 
family. LPA targets cells through at least six 
well-characterized extracellular receptors and one 
nuclear receptor (the PPARγ receptor) (4, 5). LPA is 
found at physiologically and pathophysiologically 
significant concentrations in plasma and serum, re-
spectively. LPA is typically produced by the action of 
plasma lysophospholipase D (lysoPLD), also known 
as autotaxin, on lysophosphatidylcholine (LPC) (6). In 
serum, activated platelets are one of the primary 
sources of LPA, which is produced via the action of 
lysoPLD on LPC and other lysophospholipids (7). 
LPA has been found to stimulate cell division and 
migration and to inhibit apoptosis (8). We have pre-
viously determined that LPA can stimulate lung fi-
broblast to myofibroblast differentiation (9). A similar 
differentiation step is critical to the pathogenesis of 
SSc, in that myofibroblasts are one of the primary 
sources of SSc fibrotic tissue (10, 11). Rho-associated 
kinases (ROCK), which are activated by LPA, have 
recently been found to stimulate myofibroblast dif-
ferentiation from cultured human skin SSc fibroblasts. 
In addition, ROCK stimulated the production of ex-
tracellular matrix by these cells (12). 
Sphingosine 1-phosphate (S1P), another major 
member of the PLGF family, acts as an agonist to 
membrane receptors that have close evolutionary 
links to several of the LPA receptors. S1P has been 
shown to have significant effects on lymphocytes. 
Both B- and T-cells require S1P activity to allow their 
movement out of lymphoid organs, and thymocytes 
require S1P receptor activation for release from the 
thymus (13). Although there is currently no known 
association between S1P and SSc, SSc has an auto-
immune component with reported lymphocyte in-
volvement that suggests there may be a role for S1P in 
the development and/or progression of SSc.  
In view of the high level of platelet activation 
seen in SSc (14), along with the increased myofibro-
blast activity and impaired myofibroblast apoptosis, 
we hypothesized that elevated PLGFs play a role in 
the pathogenesis of SSc, and specifically that LPA 
would be elevated in SSc subjects relative to healthy 
controls. Therefore, we designed this study to deter-
mine whether differences exist in serum LPA concen-
trations and in lysoPLD activities of SSc and control 
subjects. We chose to look at a range of different LPA 
species because of the likelihood that we would find 
differences in either a particular species or class of 
LPA (15). In addition to LPA measurement, we also 
measured and compared S1P concentrations in the 
blood of SSc versus control subjects because of the 
likely autoimmune pathogenesis of SSc and the link 
between S1P and immune cell function. Because of 
significant differences that are present between lim-
ited and diffuse SSc, we also examined the differences 
in lipid products and lysoPLD activity between sub-
jects with these two subgroups of the disease. Finally, 
we measured in SSc and control subjects the concen-
trations of additional bioactive lysophospholipids, 
including lysophosphatidylethanolamine (LPE), 
lysophosphatidylinositol (LPI) and lysophosphati-
dylserine (LPS), which are precursors of LPA.  
Subjects and Methods 
Ethics Statement. Written consent for participa-
tion in the study was obtained from all participants in 
accordance with the Helsinki II declaration, and the 
protocol was approved by the UTHSC Institutional 
Review Board. 
Subjects. SSc subjects with a history of limited or 
diffuse SSc were recruited from the Rheumatology 
Clinic of the University of Tennessee Health Science 
Center (UTHSC). All SSc subjects met the 1980 ACR 
classification criteria for clinical diagnosis of limited 
or diffuse SSc (16). Healthy controls were recruited 
from UTHSC staff. Those with a history of an organ or 
stem cell transplant, those who had used prednisone, 
cyclophosphamide, D-penicillamine, cyclosporine A, 
methotrexate, azathioprine, or other immune modu-
lator therapies within one month of study start, and 
those who were less than 18 years old were excluded 
from the study.  
Preparation of serum samples.  After an over-
night fast, blood was collected from 10 patients with 
SSc (7 with diffuse disease and 3 with limited disease) 
and from 13 healthy controls. Serum was drawn off 
after the collected blood had been left 1 h at room 
temperature and then spun at 2500 rpm for 15 min. 
Samples were stored at -80 oC until overnight ship-
ping (on dry ice) to Japan for biochemical analysis. 
Analyses were performed in a blinded fashion. The 
laboratory performing the analyses was provided the 
sample key only after the analyses were complete and 
reported. 
Lipid and lysoPLD measurements. Phospholipids. 
1-heptadecanoyl (17:0)-LPC and C17-S1P were pur-
chased from Avanti Polar Lipids (Alabaster, AL, USA). 
17:0-LPA was prepared from 17:0-LPC by the action 
of phospholipase D from Streptomyces chromofuscus, as 
described previously (17). 17:0-LPE was prepared 
from 17:0-LPC and ethanolamine hydrochloride by a 
transphosphatidylation reaction with phospholipase 
D from Actinomadura sp. (Seikagaku Kogyo; Tokyo, 
Japan) according to the method for preparation of 
phosphatidylglycerol from phosphatidylcholine (18). 
In brief, a mixture of 0.1 ml of 5 M ethanolamine hy-Int. J. Med. Sci. 2009, 6 
 
http://www.medsci.org 
170
drochloride/0.2 M acetate buffer (pH 5.5) containing 
0.1 mmol 17:0-LPC, 0.05 ml of 0.22 M CaCl2/0.02 M 
NaCl, and 0.1 ml of phospholipase D solution (8 
mg/ml) in 0.2 M acetate buffer was incubated while 
being stirred for 2 h at 30oC. After the reaction was 
stopped by addition of 2 ml chloroform/methanol 
mixture (1:1, v/v), the mixture was centrifuged at 
1300 x g for 10 min. Lipids recovered into the organic 
layer were separated by thin-layer chromatography 
on a silica gel plate (Silica gel G60; Merck; Darmstadt, 
Germany) developed with chloro-
form/methanol/20% ammonia (60:35:8, v/v). Lipid 
bands were detected by spraying of primuline under 
UV light. 17:0-LPE was extracted from silica in the 
corresponding lipid band by the method of Bligh and 
Dyer (19). Purities of 17:0-LPA and 17:0-LPE recov-
ered from the silica were checked by liquid chroma-
tography-tandem mass spectrometry (LC-MS-MS) as 
described below. 
Lipid extraction. Lipids were extracted from 
human serum samples by the modified method of 
Bligh and Dyer (19) after adjusting the aqueous phase 
pH to 9-9.5 with 20% ammonium hydroxide. To the 
lipid extract were added 5 nmol 17:0-LPC, 0.05 nmol 
17:0-LPE, 0.1 nmol 17:0-LPA, and 0.2 nmol C17 S1P. 
Most of the lipids, including LPC and LPE, were ex-
tracted into the organic layer. The lipid extract was 
dried under a stream of nitrogen gas, reconstituted 
with 0.5 ml of methanol/water mixture (1:1, v/v) 
containing 5 mM ammonium formate, and termed the 
neutral lipid fraction. The remaining aqueous layer 
was acidified to pH 2-2.5 with 1 N hydrochloric acid, 
and acidic lipids such as LPA, LPI and LPS and S1P 
were extracted into the organic layer by the method of 
Bligh and Dyer (19). The second lipid extract (acidic 
lysophospholipid fraction) was dried down under a 
stream of nitrogen gas and dissolved in 0.1 ml of ace-
tonitrile/isopropanol/methanol/water (1:1:1:1, v/v) 
mixture containing 0.2% formic acid for LC-MS-MS. 
LC-MS-MS of lysophospholipids.  LC-MS-MS 
was performed on a quadrupole-linear iontrap hybrid 
MS, 4000 QTRAPTM (Applied Biosystems/MDS Sciex; 
Concord, ON, Canada), with an Agilent 1100 LC sys-
tem combined with an autosampler (Agilent Tech-
nologies; Wilmington, DE, USA). Separation of neu-
tral lipid fractions by LC was achieved using an 
Agilent ZORBAX Eclipse XDB-C18 column (50 mm x 
1 mm; 3.5-μm particle size silica). The composition of 
the mobile phase was methanol/water (4:1, v/v) 
containing 5 mM ammonium formate, which was 
pumped at a flow rate of 0.1 ml/min for an isocratic 
elution. Separation of acidic lysophospholipids by LC 
was performed with a Tosoh TSK-ODS-100Z column 
(150 mm x 2 mm; silica with 5-μm particle size) de-
veloped with methanol/water (19:1, v/v) containing 5 
mM ammonium formate at a flow rate of 0.22 ml/min 
in an isocratic elution mode. Routinely, 5 μl aliquots 
of test solutions were applied to the mass spectrome-
ter for analysis. Lysophospholipids were analyzed by 
multiple reaction monitoring (MRM) in a positive ion 
mode for LPC and LPE or in a negative ion mode for 
LPA, LPI, LPS, and S1P. In the positive ion MRM, Q1 
and Q3 were set for the protonated molecular ion and 
[phosphorylcholine]+ at m/z 184 for LPC or [M – 141]+ 
for LPE. In the negative ion MRM, Q3 was set to [cyclic 
glycerol phosphate]- at m/z 153 for LPA and LPS, 
[phosphorylinositol - H2O]- at m/z 241 for LPI or [PO3]- 
at m/z 79 for S1P, in combination with the deproto-
nated molecular ion as Q1 for all lysophospholipids 
tested. Amounts of the different molecular species of 
LPC and LPE were calculated from the ratios of their 
areas of positive ions to those of 17:0-LPC or LPE in-
ternal standards. Similarly, the amounts of molecular 
species of LPA were calculated from the ratios of their 
peak areas of negative ions to that of 17:0-LPA, an 
internal standard. The amounts of molecular species 
of LPS and LPI were calculated from both their peak 
areas of negative ions to that of 17:0-LPA and the 
correction factors for LPI and LPS. These correction 
factors were determined to be 10.5 and 6.4, respec-
tively, based on both the extraction efficiencies of 16:0- 
and 18:1-LPS and bovine liver LPI, and the relative ion 
efficiency for LPI and LPS against 17:0-LPA by MRM 
under our conditions. 
Measurement of lysoPLD activity. LysoPLD ac-
tivity in serum was measured by the enzyme-linked 
fluorometric method for determination of choline 
produced together with LPA from exogenously 
added 0.15 mM 18:2-LPC. In our assay, performed on 
a 96-well microplate, 0.05 ml of 3.3-fold diluted serum 
was mixed with 0.025 ml of saline and 0.025 ml of LPC 
solution at 0.6 mM in saline containing 0.25% bovine 
serum albumin. The mixtures in the wells were incu-
bated at 37 oC for 9 or 24 h, and were then mixed with 
0.2 ml of assay buffer. The assay buffer was composed 
of 0.1 ml of Tris-HCl buffer (pH 8.5), 0.04 ml of 7.5 
mM 3-(4-hydroxyphenyl)propionic acid, 0.02 ml of 25 
U/ml choline oxidase and 0.04 ml of 2 U/ml horse-
radish peroxidase. With the aid of a standard line 
obtained with 0, 0.1, 0.3, 1, 3, 10, and 30 nmol/ml of 
water solution of choline chloride, the choline con-
centration was determined from the intensity of fluo-
rescence measured at 320 nm (excitation) and 404 nm 
(emission), and lysoPLD activity was calculated as 
nmol choline/ml of serum. Alternatively, serum 
lysoPLD activity of subjects with diffuse SSc and 
healthy controls was measured by quantifying LPA 
production using LC-MS-MS as described above. Int. J. Med. Sci. 2009, 6 
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Statistical analysis. Results are expressed as 
means ± S.E. Analyses were performed using the 
Kruskal-Wallis test using Excel Statcel software. All 
analyses were prespecified. P < 0.05 was considered 
statistically significant. 
Results 
Ten female SSc subjects and 14 female age- and 
race-matched healthy controls were included in this 
study. Among the SSc subjects, seven had diffuse 
disease and three had limited disease. The mean du-
ration of disease in the SSc subjects was 10.3 years, 
with a range of 3-28 years. The mean age of the SSc 
subjects was 47 years. The mean age of the controls 
was 46 years. Table 1 shows the characteristics of the 
study subjects.   
Table 1. Characteristics of individual study subjects 
Gender Race  Age  at   
Collection 
Group Disease 
 Type 
Disease 
 Duration 
(yrs) 
F  B  57  CON       
F  W  53  CON       
F  W  55  CON       
F  B  58  CON       
F  W  23  CON       
F  W  30  CON       
F  W  57  CON       
F  W  52  CON       
F  W  56  CON       
F  W  55  CON       
F  W  49  CON       
F  B  38  CON       
F  As  27  CON       
F W  50  SSC  Diffuse  3 
F W  50  SSC  Diffuse  4 
F B  64  SSC  Diffuse  9 
F W  52  SSC  Diffuse  7 
F W  49  SSC  Diffuse  3 
F B  36  SSC  Diffuse  28 
F W  21  SSC  Diffuse  11 
F W  57  SSC  Limited  19 
F W  48  SSC  Limited  10 
F W  44  SSC  Limited  9 
 
 
Measured serum concentrations of LPC, LPA, 
S1P, and dihydrosphingosine 1-phosphate (dihydro 
S1P), which is identical to S1P except that it lacks one 
double bond and acts as an agonist for all S1P recep-
tors but with a 20-fold lower affinity for S1P2 (20, 21), 
from the control and SSc groups are summarized in 
Fig. 1. LPC (Fig. 1A), a precursor of LPA, had the 
highest concentrations (16:0>18:2>18:0>18:1 and 5 
minor species) followed by LPA (Fig. 1 B) 
(18:2>20:4>16:0=18:1 and 5 minor species) and then 
S1P (Fig. 1C) (S1P>dihydro S1P). Figure 2 shows se-
rum concentrations of LPE, LPI, and LPS from control 
and SSc subjects. Of these lysophospholipids, LPE had 
the highest concentrations (18:2>18:1>16:0=20:4 and 3 
minor species), which were less than the concentra-
tions of LPA, followed by LPI (20:4>18:2>18:0>18:1 
and 5 minor species) and then LPS (18:0>18:1>20:4). 
Thus, the most predominant precursor for LPA pro-
duced by serum lysoPLD would be LPC. It is note-
worthy that the percentages of saturated molecular 
species of LPC were higher than those of LPA (Fig. 1A 
and B).  
The serum level of 20:4-LPA was significantly 
higher in the SSc group (Fig. 1B) versus the control 
group as well as in the limited SSc group versus con-
trol (2.54 ± 0.15 nmol/ml vs. 1.15 ± 0.37 nmol/ml 
for control, P= 0.026), with no differences measured 
between controls and the diffuse SSc group (1.99 ± 
0.49 nmol/ml, P = 0.088). In addition, the S1P levels 
were significantly higher in SSc vs. control groups 
(Fig. 1C), and also in the diffuse SSc group versus 
controls (data not shown). Essentially no differences 
were observed for serum levels of LPC, LPE, LPS, and 
LPI, as shown in Figs. 1A and 2A, B, and C, respec-
tively.  
Figure 3 shows LPA:LPC ratios for the different 
species of these lysophospholipids. These ratios in 
part can show the conversion status of LPC to LPA for 
the individual species and for the combined total of 
species, with values closer to 1 indicating more con-
version of LPC to LPA. Here we found a significant 
difference in the total LPC/total LPA ratio between 
control and SSc (P < 0.01) groups. There was also a 
significant difference between control and diffuse SSc 
groups (P < 0.02, data not shown). In addition, the 
values for 20:4 ratios were significantly different be-
tween control and SSc groups (P < 0.01), control and 
limited SSc (P < 0.02, data not shown) groups, and 
control and diffuse SSc (P < 0.05, data not shown) 
groups. In addition, there was a significant difference 
in the 20:3 ratio between control and SSc groups (P < 
0.05) and control and limited SSc groups (P < 0.05, 
data not shown). No significant differences were 
found between groups in the lysoPLD activity toward 
150 μM 18:2-LPC (Fig. 4). There were also no signifi-
cant differences between total and individual levels of 
LPA produced during 12 h incubation of sera from 
SSc patients and control subjects (Fig. 4).  
 Int. J. Med. Sci. 2009, 6 
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Figure 1. Serum levels of different molecular species of LPC, LPA, S1P and dihydro S1P. Open and closed bars represent 
the mean values +/- SE for 13 control and 10 SSc subjects, respectively. * P<0.05 
 
 
 
 
Figure 2. Serum levels of different molecular species of LPI, LPS, and LPE. Open and closed bars represent the mean values 
+/- SE for 13 control and 10 SSc subjects, respectively. 
 
 
 
 
Figure 3. Comparison of serum LPA:LPC ratio in control versus SSc subjects. Open and closed bars represent mean values 
+/- SE for 13 control and 10 SSc subjects, respectively. * P<0.05 Int. J. Med. Sci. 2009, 6 
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Figure 4. Serum lysoPLD activity in human control and SSc subjects. LysoPLD activity in serum from subjects with limited 
SSc (n=3), diffuse SSc (n=7) and healthy controls (n=11) was measured by quantifying choline release (closed bars). Al-
ternatively, LysoPLD activity in serum of subjects with diffuse SSc (n=4) and healthy controls (n=4) was measured by 
quantifying LPA production (open bars). No significant differences were found between any groups. 
 
Discussion 
For this study, we chose to measure not only to-
tal LPA levels in SSc versus control subjects, but also 
to measure several different specific saturated and 
unsaturated LPA species. It is now known that the 
different species of LPA have variable specificities to 
LPA receptors as well as differing potencies to cause 
cell specific cell responses (22-25). In addition, LPA 
agonists and antagonists are being modeled after dif-
ferent LPA species (26-28).  
The major findings of this study were signifi-
cantly elevated concentrations of 20:4 LPA and S1P in 
the serum of SSc subjects versus controls. The total 
serum LPA:LPC ratio, and within this, the subgroups 
of 20:3 and 20:4 LPA:LPC ratios, were also elevated in 
the SSc subjects versus controls. No significant dif-
ferences in other lysophospholipid mediators, in-
cluding LPE, LPI, and LPS, were found between con-
trol and SSc subjects. In addition, there were no dif-
ferences observed in lysoPLD enzymatic activity be-
tween the SSc subjects and controls.  
The serum level of LPA appears to be controlled 
by a balance between LPA-producing and 
LPA-degrading enzymatic activities. We postulate 
that the elevated LPA and LPA:LPC ratios found in 
SSc subjects may be linked to reduced activity of a 
postulated LPA-degrading lysophospholipase in the 
serum of SSc subjects that would preferentially hy-
drolyze highly polyunsaturated LPAs, such as the 
20:4 species, over other LPA species. Increased LPA 
synthesis is likely not responsible for these elevated 
values because we found no increase in lysoPLD ac-
tivity in any of the SSc groups. Our findings of sig-
nificantly higher LPA:LPC ratios in the polyunsatu-
rated species over saturated and monounsaturated 
species in serum samples from SSc patients and con-
trol subjects is consistent with a previous finding that 
sn-1-lyso-LPC, formed via hydrolysis of phosphati-
dylcholine by phospholipase A1, is a superior sub-
strate for lysoPLD in human serum and plasma as 
compared to sn-2-lyso-LPC, which is generated by 
hydrolysis of phosphatidylcholine by phospholipase 
A2 (29). It will be interesting to measure PLA1 vs. PLA2 
activity in control and diffuse SSc subjects once the 
molecular identity of PLA1 is determined.   
Among the many different LPA subtypes meas-
ured in this study, 20:4 LPA was consistently elevated 
in the SSc subjects (both limited and diffuse) versus 
control subjects. 20:4 LPA has been used in a number 
of studies as an example of an sn-1 unsaturated LPA. 
Overall, 20:4 has been shown to have broad specificity 
for the different LPA receptors (23). In regard to SSc, 
20:4 LPA has been found to have a high plate-
let-activating potency (24, 25). While activated plate-
lets are a common feature of SSc, and activated plate-
lets are known to release LPA, the presence of ele-
vated 20:4 LPA could act in a positive feedback man-
ner to perpetuate platelet activation. From an immune 
standpoint, unsaturated LPAs, with 20:4 LPA being 
one of the species tested, were found to be chemotac-
tic to immature (but not mature) dendritic cells. This 
response was mediated at least in part through the 
LPA3 receptor (30). This is potentially important, 
given recent evidence for altered antigen processing 
in SSc (31). 
When stratifying by SSc disease types, the total 
serum LPA:LPC ratio and serum 20:4 LPA:LPC ratio 
were significantly elevated in the diffuse SSc subjects 
versus controls. Although we had a small sample size 
of subjects with limited SSc, we found that serum 20:4 
LPA and the 20:3 and 20:4 LPA:LPC ratios were sig-Int. J. Med. Sci. 2009, 6 
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nificantly higher in the limited SSc group versus con-
trol subjects. In addition, elevated serum S1P concen-
trations approached significance in diffuse SSc and 
limited SSc subjects versus controls (P = 0.05 and 0.09, 
respectively). These LPA:LPC ratio and S1P patterns 
all follow the general pattern of these parameters be-
ing higher in SSc subjects versus controls.  
Platelets are known to play a pathological role as 
a main source of circulating S1P by accumulating and 
releasing S1P after local blood coagulation, whereas 
erythrocytes are considered to be the main source of 
plasma S1P (32). It is quite likely that the elevated 
level of S1P in sera from SSc patients is due to the 
activation of platelets during blood coagulation in 
vitro. The biological/clinical significance of our find-
ings relates to both the immune etiology and fibrotic 
disposition of SSc. In regard to the immune system, 
the elevated S1P concentrations found in SSc subjects 
may relate to the lymphocyte involvement in the 
autoimmune genesis of SSc. S1P is required for lym-
phocyte egress from lymphoid organs; in addition, 
thymocytes require S1P receptor activation to be re-
leased from the thymus (13). Therefore, elevated S1P 
may act to increase the pool of immune cells available 
for autoimmune responses. Interestingly, an experi-
mental S1P agonist, FTY720, is being tested as a pos-
sible pharmacological agent to treat immune rejection 
following transplants and autoimmune diseases (33). 
Although it acts as an S1P receptor agonist, FTY720 
actually leads to S1P receptor internalization, leaving 
the receptors unavailable for binding with S1P and 
thus antagonizing the effects of S1P. The result is the 
trapping of lymphocytes within lymph nodes and 
Peyer’s patches and a marked reduction of lympho-
cytes in the circulation (34). Thus, it is theoretically 
possible that treatment with FTY720 or other agents 
directed at S1P might have effects in SSc. 
Elevated LPA and LPA/LPC ratios may be in-
volved in the fibrotic component of SSc. A recent 
study found that elevated plasma LPA levels and 
higher serum lysoPLD activity were associated with 
hepatitis C and its associated liver fibrosis (35). Serum 
LPA was not examined. The authors of this study 
postulate that elevated LPA contributed to the hepatic 
fibrosis through its proliferative and anti-apoptotic 
effect on hepatic stellate cells. In a second recent study 
linking LPA to a fibrotic pathology, LPA was found to 
be elevated in the bronchoalveolar lavage fluid of 
patients with idiopathic pulmonary fibrosis, and in-
hibition of the LPA1 receptor reduced the chemotactic 
activity of this fluid towards fibroblasts (36). The au-
thors speculate that increased vascular leakage asso-
ciated with LPA1 receptor activation may lead to in-
creased fibrin deposition and a corresponding fibrotic 
cascade in injured airspaces. They also note that S1P 
reduces vascular permeability (37). It is possible that 
elevations in LPA and/or S1P concentrations may 
have altered vascular permeability in our SSc subjects, 
although this awaits further study. 
Our previous work indicates that LPA-induced 
myofibroblast differentiation may be involved in SSc 
fibrotic activity and possibly pathological fibrosis in 
general. Myofibroblasts are cells with smooth muscle 
characteristics (they contain a smooth muscle actin 
and are contractile) and are typically derived from 
fibroblasts or epithelial cells. In SSc, they also appear 
to be derived from circulating blood-derived mono-
nuclear cells (38). Myofibroblasts are widely accepted 
to be major contributors to tissue and organ fibrosis 
(39-41). Not only did we demonstrate that LPA could 
trigger fibroblast to myofibroblast differentiation (9), 
but we have also described an LPA-activated Cl- cur-
rent (IClLPA) that is active in myofibroblasts but not 
myofibroblast precursors. We have observed IClLPA in 
myofibroblasts from the lung (9) and cornea (42, 43) 
and from the skin, heart, and liver (unpublished data). 
We have demonstrated that blocking IClLPA activity 
can prevent fibroblast to myofibroblast differentiation 
(9). 
In conclusion, we measured 10 different LPC and 
LPA species (2 saturated and 8 unsaturated) along 
with S1P and lysoPLD activity in the serum of control 
subjects and subjects with confirmed SSc. We demon-
strated significantly increased serum 20:4 LPA and 
S1P concentrations in SSc subjects versus controls, 
along with elevated LPA:LPC ratios of two different 
unsaturated (but not saturated) phospholipid species, 
as well as the ratio of all species combined (total). We 
also determined that there was no difference in the 
enzymatic activity of lysoPLD, which generates LPA 
from LPC, between control and SSc subjects. Our re-
sults are potentially of real clinical significance in a 
disease for which there remains no cure and no di-
rected therapies. Although we can control some 
manifestations of the disease, no pharmacological 
therapies are currently available that alter the under-
lying systemic fibrosis that is the hallmark of SSc. Our 
study suggests that directed pharmacological inhibi-
tion of LPA and S1P receptors (novel LPA and S1P 
receptor agonists and antagonists are currently under 
development) (34, 44) may represent an innovative 
pathway for targeting the fibrosis and autoimmunity 
in SSc. 
Limitations 
The major limitation of this study is the relative 
rarity of the disease and subsequent difficulty in re-
cruiting large numbers of SSc subjects, especially with Int. J. Med. Sci. 2009, 6 
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both diffuse and limited disease, making it difficult to 
adequately power these comparisons. Despite this 
limitation, we were able to see significant results be-
tween the groups tested, indicating what is likely 
clinically significant differences in the levels of these 
bioactive lipids and the LPA:LPC ratios between con-
trol and SSc subjects.  
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